Hosted on MSN5d
Denali Starts Dosing in Phase II Parkinson's Disease Study
Denali Therapeutics Inc. DNLI initiated dosing in a global mid-stage study, BEACON, on BIIB122 (DNL151). BIIB122, an ...
news.stocktradersdaily9d
When (DNLI) Moves Investors should Listen
Check the time stamp on this data. Updated AI-Generated Signals for Denali Therapeutics Inc. (DNLI) available here: DNLI.
Business Insider7d
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the ...
Denali Therapeutics announces first patient dosed in Phase 2a study of BIIB122
Denali Therapeutics (DNLI) announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich ...
Pitcairn Co. Takes Position in Denali Therapeutics Inc. (NASDAQ:DNLI)
Pitcairn Co. purchased a new position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the 3rd quarter, ...
Yahoo Finance27d
We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely
So, the natural question for Denali Therapeutics (NASDAQ:DNLI) shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the company's annual negative ...
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.